Leukemia Articles | Page 2

Combinations Have Potential to Shift CLL Treatment Paradigm
Richard Furman, MD, discusses the current management of chronic lymphocytic leukemia and the future of combinations, including venetoclax and ibrutinib, for this patient population.
Ivosidenib Shows High Single-Agent Activity for IDH1-mutant AML
The IDH1 inhibitor ivosidenib induced a complete response (CR) or CR with partial hematologic recovery for 30.4% of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.
CLL in the Era of Targeted Therapies
Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.
The combination of venetoclax and rituximab reduced the risk of disease progression or death by 83% versus bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. 
Rituximab Leads to Faster Response in CLL, But PFS Not Improved
Despite a faster time to complete remission, the addition of rituximab (Rituxan) to ibrutinib (Imbruvica) did not improve PFS or overall survival OS compared with ibrutinib alone in patients with CLL. 
Ibrutinib/Venetoclax Combo Impresses in Early CLL Data
The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) elicited a complete response (CR) or CR with incomplete hematologic recovery rate of 47% for patients with relapsed/refractory chronic lymphocytic leukemia.
Oncology Experts Highlight Practice-Changing Abstracts at ASH 2017
Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.
AML Field Advances With New Agents, But More Work Remains
Olga Frankfurt, MD, discusses advances in the field of AML and challenges that lie ahead.
Better Patient Selection Needed for AML Therapies
Alexander E. Perl, MD, discusses the future of FLT3 inhibitors, current obstacles with treating patients with acute myeloid leukemia, and what pivotal trial results the community can expect to hear in the coming months.
Treatment Strategies Expanding for Elderly Patients With CLL
Jacqueline Claudia Barrientos, MD, discusses the appropriate treatment strategies for elderly patients with chronic lymphocytic leukemia.
Publication Bottom Border
Border Publication